{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-035061","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-05-14T20:02:06+00:00","discovered_at":"2026-05-14T20:03:31.375398+00:00","generated_at":"2026-05-14T21:02:47.199909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB","bullets":["Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.","Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.","Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.","Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.","2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-035061","json":"https://secwatch.observer/filing/0001628280-26-035061.json","markdown":"https://secwatch.observer/filing/0001628280-26-035061.md","text":"https://secwatch.observer/filing/0001628280-26-035061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/0001628280-26-035061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/sgmo-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:02:47.199909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53facdbf63fad0b03706d22a521d29ed9a6ddd14","claim":"SANGAMO THERAPEUTICS, INC reported first quarter ended March 31, 2026 results: revenue $1.4 million, net income $31.0 million, EPS $0.08 per share.","evidence_excerpt":"First Quarter 2026 Financial Results Consolidated net loss for the first quarter ended March 31, 2026 was $31.0 million, or $0.08 per share, compared to a consolidated net loss of $30.6 million, or $0.14 per share, for the same period in 2025. Revenues Revenues for the first quarter ended March 31, 2026 were $1.4 million, compared to $6.4 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/0001628280-26-035061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.4 million"},{"label":"Net income","value":"$31.0 million"},{"label":"EPS","value":"$0.08 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}